Bone Turnover Markers — What Blood Tests Can Tell You

• What bone turnover markers are and why they matter
• Formation markers: P1NP and BAP (the "building team")
• Resorption markers: CTX and NTX (the "demolition team")
• How to interpret high or low values
• How doctors use these markers to guide treatment
• Important limitations to understand

As we described in Your Bones Are Alive, your bones are constantly being broken down (resorption) and rebuilt (formation) in a process called remodeling. Every time this happens, the cells involved release specific molecules into the bloodstream. By measuring these molecules, doctors can assess how fast bone remodeling is occurring.

Think of it this way: if bone remodeling is a construction site, bone turnover markers are like the dust and noise that tell you how much activity is going on -- even if you cannot see inside the building.

There are two main categories:

• Formation markers -- released when new bone is being built. These indicate the activity of osteoblasts (the building team).
• Resorption markers -- released when bone is being broken down. These indicate the activity of osteoclasts (the demolition team).

While a DXA scan shows you where things stand, bone turnover markers show you where things are heading.

When osteoblasts build new bone, they produce specific proteins and enzymes that spill into the bloodstream. Measuring these tells your doctor how actively your body is producing new bone.

P1NP (Procollagen type 1 N-terminal propeptide)

P1NP is currently the preferred formation marker recommended by the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry (IFCC).

• What it measures: When osteoblasts produce type 1 collagen (the main structural protein of bone), they release a fragment called P1NP into the blood
• What it reflects: The rate at which new bone collagen is being formed
• Sample type: Blood test (serum)
• Key advantage: P1NP is relatively stable throughout the day, making it less affected by the timing of the blood draw

BAP (Bone-specific Alkaline Phosphatase)

• What it measures: An enzyme produced by osteoblasts during the mineralization phase of bone formation (when calcium and other minerals are deposited onto the collagen framework)
• What it reflects: The rate of bone mineralization
• Sample type: Blood test (serum)
• Note: Total alkaline phosphatase (ALP) is a common blood test, but it includes contributions from the liver and other organs. BAP is the bone-specific version and is more accurate for assessing bone formation

What high or low formation markers mean

When osteoclasts break down bone, they release fragments of bone tissue into the bloodstream and urine. Measuring these fragments tells your doctor how actively bone is being demolished.

CTX (C-terminal telopeptide of type 1 collagen)

CTX is the preferred resorption marker recommended by the IOF/IFCC.

• What it measures: When osteoclasts break down bone collagen, they release small fragments called cross-linked telopeptides. CTX is a specific fragment from the C-terminal end
• What it reflects: The rate of bone collagen breakdown
• Sample type: Blood test (serum) -- this is called s-CTX or beta-CTX
• Important: CTX levels vary significantly throughout the day and are affected by eating. A fasting morning blood draw is essential for accurate results

NTX (N-terminal telopeptide of type 1 collagen)

• What it measures: Similar to CTX, but from the N-terminal end of the collagen molecule
• Sample type: Can be measured in blood (serum) or urine
• Note: Urine NTX was widely used in the past but has largely been replaced by serum CTX in clinical practice due to greater convenience and reliability

What high or low resorption markers mean

A typical bone marker blood test report will show your values alongside a reference range. Here is a simplified example:

In this example, P1NP is within the normal range (bone building is proceeding normally), but CTX is slightly elevated (bone breakdown is higher than average). This pattern could suggest that bone is being broken down a bit faster than it is being replaced -- a common finding in postmenopausal women who are not yet on treatment.

Bone marker results are best interpreted by your doctor in the context of your overall health, DXA results, and clinical history. A single value in isolation can be misleading.

1. Assessing treatment response

This is the most common clinical use. After starting an osteoporosis medication, your doctor may order bone markers at 3-6 months to see if the treatment is working:

• Anti-resorptive medications (alendronate, risedronate, denosumab): CTX should decrease significantly within 3-6 months. A drop of 25-30% or more from baseline generally indicates the medication is effective.
• Bone-building medications (teriparatide, romosozumab): P1NP should increase, indicating new bone formation is being stimulated.

This is valuable because DXA scans can take 1-2 years to show measurable changes. Bone markers provide a much earlier signal.

2. Monitoring medication adherence

If a patient is prescribed a bisphosphonate but their CTX levels remain unchanged after 3-6 months, it may suggest the medication is not being absorbed properly (bisphosphonates must be taken on an empty stomach with water) or is not being taken regularly.

3. Baseline assessment

Some doctors order bone markers at the same time as a DXA scan to get a fuller picture of bone health. A person with borderline osteopenia but very high resorption markers may be at greater risk of rapid bone loss than their DXA score alone would suggest.

4. Detecting high-turnover states

Elevated markers (both formation and resorption) can indicate conditions like Paget's disease, hyperparathyroidism, or metastatic bone disease. They can also flag secondary causes of osteoporosis that may need separate treatment.

Bone turnover markers are useful tools, but they come with some important caveats:

Biological variability

Bone markers naturally fluctuate from day to day and even throughout the day. CTX in particular shows a strong circadian rhythm -- levels are highest in the early morning and lowest in the afternoon. Eating also suppresses CTX levels. This is why a fasting morning blood draw is standard.

Conditions that affect results

Several factors can influence bone marker levels independent of osteoporosis:

• Recent fractures -- markers will be elevated as the body heals
• Kidney disease -- impairs marker clearance and skews results
• Liver disease -- can affect some markers (especially total ALP)
• Vitamin D deficiency -- can elevate resorption markers
• Pregnancy and growth -- naturally elevate all bone markers

They are not diagnostic

Bone markers alone cannot diagnose osteoporosis. They are complementary to DXA scans, not a replacement. A normal DXA with elevated markers, or low bone density with normal markers, each tells a different story.

Limited standardization

Different laboratories may use different assays and reference ranges. For the most accurate comparison over time, try to have your bone markers tested at the same laboratory.

Bone markers are a powerful addition to your doctor's toolkit, but they work best when combined with DXA scans and clinical assessment -- not in isolation.

Q. Do I need to fast before bone marker blood tests?

For CTX (resorption marker): Yes. A fasting morning blood draw is strongly recommended because eating suppresses CTX levels. Typically, you should fast overnight and have the blood drawn in the morning before eating.

For P1NP (formation marker): Fasting is less critical because P1NP is relatively stable throughout the day. However, many doctors order both markers together, so a fasting morning draw covers both.

Q. How often are bone markers tested?

It depends on the clinical situation. Common patterns include:

• Baseline: When osteoporosis is first diagnosed or when treatment begins
• 3-6 months after starting medication: To check if treatment is working
• Annually: For ongoing monitoring in some cases
• When changing medications: To establish a new baseline

Q. My bone markers are high. Does that mean I have osteoporosis?

Not necessarily. High bone markers indicate increased bone turnover, which can occur in many situations -- including healing fractures, vitamin D deficiency, hyperparathyroidism, and other conditions. High turnover is a risk factor for bone loss, but diagnosis of osteoporosis requires a DXA scan. Think of it this way: high markers suggest your bones are very active, but only a DXA scan tells you whether the net result is adequate bone density.

Q. Can I request bone marker tests on my own?

In some countries and healthcare systems, you can request laboratory tests directly. However, interpreting the results requires clinical context. It is best to have your doctor order and review them so the results can be properly interpreted alongside your medical history, DXA results, and other findings.

Q. Are there other bone markers I should know about?

The ones most commonly used in clinical practice are P1NP and CTX, as recommended by the IOF/IFCC. Other markers you might encounter include:

• Osteocalcin -- a formation marker produced by osteoblasts
• TRACP-5b -- a resorption marker released by osteoclasts (less affected by kidney function than CTX)
• Deoxypyridinoline (DPD) -- a urine resorption marker, now largely replaced by serum CTX

Your doctor will choose the most appropriate markers based on your clinical situation and what is available at your local laboratory.

• Vasikaran S et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis International, 2011; 22: 391-420. (IOF/IFCC Joint Position Statement)
• Eastell R et al. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes & Endocrinology, 2017; 5(11): 908-923.
• International Osteoporosis Foundation (IOF). Bone Turnover Markers. https://www.osteoporosis.foundation/health-professionals/diagnosis/bone-turnover-markers
• Szulc P, Delmas PD. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporosis International, 2008; 19: 1683-1704.
• Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nature Reviews Rheumatology, 2012; 8: 379-389.

This site receives founding sponsorship from [sponsor placeholder]. Article content is independently produced by the editorial team with no sponsor involvement. See our conflict of interest policy for details.